A novel chelating agent lessens the toxicity of radiopharmaceutical therapy targeting the prostate-specific membrane antigen.

Published Date: 12 Jun 2024

Research presented at the 2024 Society of Nuclear Medicine and shows that a recently developed chelator can significantly reduce off-target toxicity in prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Sub-Q Ketamine is Safe and Very Effective for Severe Depression.

2.

Study indicates that exercise can help colon cancer survivors live as long as matched individuals

3.

Contradictory Results Are Found in Two Pembrolizumab Trials for Head and Neck Cancer.

4.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?

5.

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot